THYROLAR-1
LOE ApproachingNDAORALTABLET
Approved
Nov 1969
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 23h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
THYROLAR-1 is an oral tablet approved in 1969 for thyroid hormone replacement therapy. The mechanism of action and specific indications are not currently documented in available data. This is a legacy small-molecule product marketed by AbbVie.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100); team sizing and resource allocation likely declining as market exclusivity erodes.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
THYROLAR-1 offers limited career development opportunity given its approaching loss of exclusivity and minimal linked job postings. Roles on this product are typically focused on maximizing cash flow and managing market transition rather than growth or innovation.
Brand Manager (Legacy/Portfolio)Field Sales
Worked on THYROLAR-1 at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.